Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
We are seeking an experienced and strategic Vice President, Biostatistics. This role may be based in a hybrid capacity from our Waltham, MA office or remotely from the East Coast. Reporting to the Chief Medical Officer, you will provide executive leadership across biostatistics activities, with an initial focus on CR-001, a PD-1/VEGF bispecific antibody, our lead asset. You will build the team, set the strategy, and be accountable for the statistical framework that supports our pipeline from IND through registration and BLA submission, with a strong emphasis on oncology drug development within a biotech environment. You will serve as the statistical voice of the organization — shaping the quantitative foundation of every program in our pipeline. This role is based in Waltham, MA and you must have experience in the oncology space.